Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      The Effect of Positive Inotropes on the Failing Human Myocardium

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents. We studied the contractile effects of a range of inotropic agents on papillary muscle strips from healthy and failing human hearts. Specimens were obtained from patients with different grades of heart failure. These included individuals undergoing mitral valve replacement (New York Heart Association Class II-III) or receiving heart transplantation (New York Heart Association Class IV). Heart failure was associated with attenuation of myocardial contractile responses to dobutamine, histamine, 3-isobutyl-1-methylxanthine, and the phosphodiesterase inhibitors, milrinone and pimobendan. However, pretreatment of the papillary muscle with isoprenaline augmented the positive inotropic effect observed with the phosphodiesterase inhibitors. The contractile response to ouabain was not influenced by the presence of heart failure. We conclude that, unlike β-adrenoceptors, cardiac glycoside receptors in the myocardium are not down regulated in the presence of heart failure.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-6520-2
          978-3-318-01962-9
          0008-6312
          1421-9751
          1997
          1997
          19 November 2008
          : 88
          : Suppl 2
          : 7-11
          Affiliations
          Department of Internal Medicine, University of Cologne, Germany
          Article
          177478 Cardiology 1997;88:7–11
          10.1159/000177478
          9142430
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Paper

          Comments

          Comment on this article